SIGA Investor Relations Material
Access more data
SIGA Technologies Inc is a commercial-stage pharmaceutical company. The Company's lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is currently undergoing a Phase III clinical assessment while Siga's RTS,S/AS01 adjuvanted vaccine product candidate has been approved by WHO as part of the INDEPENDENCE clinical program to be used in case of smallpox vaccine shortage and emergencies. From a strategic alliance with Cipla Therapeutics, SIGA plans to deliver sustained innovation and access to antibacterial drugs primarily against biothreats.
NIBE: Creating Millionaires and a Greener Future
NIBE, just like IKEA, was founded in a rural part of Sweden called Småland. The company offers a wide range of pumps, wood stoves, and solar panels.
6 Dec 2023
The Story of Jensen Huang and Nvidia
When looking at NVIDIA’s Jensen Huang today, it is easy to stereotype him as your archetypical big tech CEO. He doesn’t wear suits like a Wall Street Chairman, instead opting to wear his now-iconic leather jackets and casual polo shirts.
6 Dec 2023
Neglect of Probability: A Hidden Risk in Decision Making
The concept of "probability" should take center stage in our decision-making processes.
4 Dec 2023
🇺🇸 United States